Skip to main content

Original Research

Todd Williamson, MsC; Rajesh Kamalakar, MS; Augustina Ogbonnaya, MPH; Erin A. Zagadailov, PharmD, MS; Michael Eaddy, PharmD, PhD; Charlie Kreilick, MBA
The Challenge of Rosacea Treatment
Atheer A. Kaddis, PharmD
Tope Olufade, PhD, MPH; Amanda M. Kong, MPH; Nicole Princic, MS; Paul Juneau, MS; Rucha Kulkarni, MPH; Kui Zhang, MD; Catherine Datto, MD, MS
The Opioid Epidemic: Healthcare Utilization and Cost Considerations
Jack E. Fincham, PhD, RPh
Jill R. Davis, MS; Bingcao Wu, MS; David M. Kern, PhD; Ozgur Tunceli, PhD; Kathleen M. Fox, PhD; John Horton, MS; Randall F. Legg, PharmD, MBA; Frank Trudo, MD, MBA
When an Outcome Is Overdetermined: Nonadherence, Utilization, and the Impetus for Research in COPD
Michael F. Murphy, MD, PhD
Bettina M. Beech, DrPH, MPH; Tristan Cordier, MPH; Laura E. Happe, PharmD, MPH; Laura Trunk, MD; Gilbert S. Haugh, MS; Richard Kwong, MPH; Vipin Gopal, PhD; Roy A. Beveridge, MD
Patients’ Choice for Site of Care Motivated by More Than Cost Alone
James T. Kenney, Jr, RPh, MBA
An Ounce of Prevention Is Not a Choice a Patient Gets to Make for Late-Stage Cancer
Generic Imatinib: Can It Provide Significant Cost Relief for Patients?
You Cannot Manage What You Cannot Measure
A Teachable Moment in Health Benefits Design
Counting on a Run of Value-Based Benefit Design
Response-Guided Therapy an Appropriate Tool for Evaluating Treatment Protocols and Costs of Drug Therapies
Page 10 of 11
Results 91 - 100 of 109